Systematic literature review of asthma biologic self-administration enhanced by a patient perspective

Simona Boccaletti MSc , Rafael Alfonso-Cristancho PhD , Waseem Ahmed MBA , Lehanne Sergison , Adaeze Eze MSc , Prashant Auti MS (Pharm) , Cathelijne Alleman MSc , Lohit Badgujar PhD , Nicholas Halfpenny MSc , Dorothea Heldt MSc
{"title":"Systematic literature review of asthma biologic self-administration enhanced by a patient perspective","authors":"Simona Boccaletti MSc ,&nbsp;Rafael Alfonso-Cristancho PhD ,&nbsp;Waseem Ahmed MBA ,&nbsp;Lehanne Sergison ,&nbsp;Adaeze Eze MSc ,&nbsp;Prashant Auti MS (Pharm) ,&nbsp;Cathelijne Alleman MSc ,&nbsp;Lohit Badgujar PhD ,&nbsp;Nicholas Halfpenny MSc ,&nbsp;Dorothea Heldt MSc","doi":"10.1016/j.jacig.2024.100334","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Several biologics for the treatment of severe asthma are available as self-administration devices.</div></div><div><h3>Objective</h3><div>We performed a systematic literature review to understand the use, benefits, and challenges of these self-administration devices.</div></div><div><h3>Methods</h3><div>Electronic databases and conference proceedings were searched using terms for asthma, biologic treatment, and at-home/self-administration (GSK study 213094). Publications were scanned for relevance using prespecified Population, Intervention, Comparison, Outcomes, Study Design (PICOS) criteria. Data on efficacy, safety, patient experience, and economic outcomes were extracted; study quality was assessed. A firsthand patient perspective was obtained.</div></div><div><h3>Results</h3><div>Thirty-five of 504 records met the inclusion criteria. Across four phase 3 studies, ≥95% of biologic self-administrations were successful on the basis of predefined criteria. At-home self-administration was preferred over in-clinic administration by 43-96% of patients across 5 studies. Most patients (≥89%) in two phase 3 studies reported completing self-administration easily without repeated reference to instructions; high proportions of patients (≥98%) were confident in their ability to self-administer their biologic, and ≥96% rated it as extremely, very or moderately easy to self-administer. Across 16 studies reporting efficacy data, there was evidence of reduced blood eosinophil counts and improved asthma control with biologic self-administration, with improved health-related quality of life shown across 6 studies. Economic outcomes data were limited. From a patient perspective, autonomy is the major benefit of self-administration.</div></div><div><h3>Conclusion</h3><div>Although more evidence is needed, this systematic literature review provides consistent evidence of high injection success rates and, supported by a patient perspective, preference for self-administration of biologics among patients with severe asthma.</div></div>","PeriodicalId":75041,"journal":{"name":"The journal of allergy and clinical immunology. Global","volume":"3 4","pages":"Article 100334"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772829324001309/pdfft?md5=d952829a934e948b9e28bfd850c74b84&pid=1-s2.0-S2772829324001309-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of allergy and clinical immunology. Global","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772829324001309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Several biologics for the treatment of severe asthma are available as self-administration devices.

Objective

We performed a systematic literature review to understand the use, benefits, and challenges of these self-administration devices.

Methods

Electronic databases and conference proceedings were searched using terms for asthma, biologic treatment, and at-home/self-administration (GSK study 213094). Publications were scanned for relevance using prespecified Population, Intervention, Comparison, Outcomes, Study Design (PICOS) criteria. Data on efficacy, safety, patient experience, and economic outcomes were extracted; study quality was assessed. A firsthand patient perspective was obtained.

Results

Thirty-five of 504 records met the inclusion criteria. Across four phase 3 studies, ≥95% of biologic self-administrations were successful on the basis of predefined criteria. At-home self-administration was preferred over in-clinic administration by 43-96% of patients across 5 studies. Most patients (≥89%) in two phase 3 studies reported completing self-administration easily without repeated reference to instructions; high proportions of patients (≥98%) were confident in their ability to self-administer their biologic, and ≥96% rated it as extremely, very or moderately easy to self-administer. Across 16 studies reporting efficacy data, there was evidence of reduced blood eosinophil counts and improved asthma control with biologic self-administration, with improved health-related quality of life shown across 6 studies. Economic outcomes data were limited. From a patient perspective, autonomy is the major benefit of self-administration.

Conclusion

Although more evidence is needed, this systematic literature review provides consistent evidence of high injection success rates and, supported by a patient perspective, preference for self-administration of biologics among patients with severe asthma.
从患者角度出发,对哮喘生物制剂自我管理进行系统性文献回顾
方法使用哮喘、生物制剂治疗和居家/自我给药等术语检索电子数据库和会议论文集(葛兰素史克研究 213094)。使用预先指定的人群、干预、比较、结果、研究设计(PICOS)标准对出版物进行相关性扫描。提取有关疗效、安全性、患者体验和经济结果的数据;评估研究质量。结果504 份记录中有 35 份符合纳入标准。在四项 3 期研究中,根据预定义标准,≥95% 的生物制剂自我给药获得成功。在 5 项研究中,43%-96% 的患者选择在家自行用药,而非在诊所用药。在两项三期研究中,大多数患者(≥89%)表示无需反复参考说明书就能轻松完成自我给药;很高比例的患者(≥98%)对自己自我给药生物制剂的能力充满信心,≥96%的患者将自我给药评为 "非常容易"、"非常容易 "或 "比较容易"。在16项报告疗效数据的研究中,有证据表明自行使用生物制剂可降低血液中的嗜酸性粒细胞计数,改善哮喘控制,其中6项研究显示与健康相关的生活质量有所改善。经济效果数据有限。结论虽然还需要更多的证据,但这篇系统性文献综述提供了一致的证据,证明注射成功率高,而且在患者观点的支持下,重症哮喘患者更倾向于自行使用生物制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
The journal of allergy and clinical immunology. Global
The journal of allergy and clinical immunology. Global Immunology, Allergology and Rheumatology
CiteScore
0.70
自引率
0.00%
发文量
0
审稿时长
92 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信